Renal Cancer Clinical Trial
Official title:
Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
This research study is studying two drugs at different time points as a possible treatment for advanced renal cell cancer The drugs involved in this study are: Nivolumab Ipilimumab
This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of investigational drugs to learn whether the drugs work in treating a specific disease. "Investigational" means that the intervention is being studied. Nivolumab and ipilimumab are antibodies (a type of human protein) that work to stimulate your body's immune system to fight tumor cells. The FDA (the U.S. Food and Drug Administration) has approved nivolumab as a treatment option for this disease; however, the FDA has not approved the way nivolumab and ipilimumab are being administered in this study. Ipilimumab is FDA approved for the treatment of melanoma (skin cancer) and has been previously studied in renal cell cancer. This study is being done to evaluate nivolumab treatment strategies based on each patients individual response to treatment. In participants who have a response to treatment, nivolumab will be stopped and participants will be closely monitored. In participants who do not have a response to treatment,the investigators will investigate whether the addition of ipilimumab improves a participant response to treatment. Participant blood and tissue samples will be collected to learn about how certain biomarkers and genes relate to participant outcomes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03634540 -
A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)
|
Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT00531284 -
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05842044 -
NSAID Use After Robotic Partial Nephrectomy
|
Phase 2 | |
| Recruiting |
NCT05387863 -
Decision Aid (DA) for Renal Patients
|
N/A | |
| Terminated |
NCT02669914 -
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
|
Phase 2 | |
| Completed |
NCT04933604 -
LPN in Patients With High-complex Renal Tumors
|
||
| Withdrawn |
NCT03390413 -
Robot-assisted Surgical Resection vs. Cryoablation of Localised Renal Cancer
|
N/A | |
| Recruiting |
NCT05119335 -
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
|
Phase 1/Phase 2 | |
| Suspended |
NCT04115254 -
Stereotactic Magnetic Resonance Guided Radiation Therapy
|
N/A | |
| Enrolling by invitation |
NCT02609269 -
Decipher Genomics Resource for Intelligent Discovery
|
||
| Terminated |
NCT01453595 -
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
|
Phase 1/Phase 2 | |
| Completed |
NCT01444456 -
Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia
|
N/A | |
| Completed |
NCT02811250 -
Stereotactic Radiotherapy for Renal Cancers
|
N/A | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00399152 -
Perifosine + Sunitinib Malate for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00458536 -
Vaccination of Patients With Renal Cell Cancer With Dendritic Cell Tumor Fusions and GM-CSF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03693014 -
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
|
Phase 2 | |
| Completed |
NCT00418496 -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT06051162 -
HPI Effect in Robotic Urological Surgery on AKI
|
N/A |